



S/N 10/608,865

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lewin et al.	Examiner:	SULLIVAN, DANIEL M
Serial No.:	10/608,865	Group Art Unit:	1636
Filed:	June 27, 2003	Docket No.:	11669.0196USC1
Conf. No.:	8197	Customer No.:	23552
Title:	GENES ASSOCIATED WITH OBESITY AND METHODS FOR USING THE SAME		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 841296465 US
Date of Deposit: July 6, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

By:

Name:

Lynnda Kraft
Lynnda Kraft

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Please charge Deposit Account No. 13-2725 for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903


Date:

July 6, 2006



Kathy M. Kowalchuk

Kathy M. Kowalchuk
Reg. No. 36,848
KMK:lek



INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.0196USC1

Application Number:

10/608,865

Applicant: Lewin et al.

Filing Date: June 27, 2003

Group Art Unit: 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	NCBI, Accession No. AAA39376, April 27, 1993
	NCBI Accession No. M55669, April 27, 1993
	NCBI Accession No. AAB32656, July 27, 1995
	NCBI Accession No. NM_002594, March 19, 1999
	Heymsfield et al, 1999, <i>JAMA</i> , 282(16)1568-1575 "Recombinant Leptin for Weight Loss in Obese and Lean Adults"
	Nilaweera et al., 2003, <i>Neuroscience</i> , 119:713-720 "Precursor-Protein Covertase 1 Gene Expression in the Mouse Hypothalamus: Differential Regulation by <i>ob</i> Gene Mutation, Energy Deficit and Administration of Leptin, and Coexpression with Prepro-Orexin"
	Sanchez et al., 2004, <i>The Journal of Clinical Investigation</i> , 114(3):357-369 "Regulation of hypothalamic prohormone convertases 1 and 2 and effects on processing of prothyrotropin-releasing hormone"
	Seidah et al., 1999, <i>Annals New York Academy of Sciences</i> , 885:57-74 "The Subtilisin/Kexin Family of Precursor Convertases - Emphasis on PC1, PC2/7B2, POMC and the Novel Enzyme SKI-1"

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.